Retrospective Study to Compare Outcomes in 159 Patients Undergoing First Autologous Stem Cell Transplantation for Myeloma Treated with Melphalan 140 mg/m² or 200 mg/m²

Umut Yılmaz; Şükran Erdem Nurcan; Deniz Özmen; Ayşe Salihoğlu; Ahmet Emre Eşkazan; Şeniz Öngören; Zafer Başlar; Teoman Soysal; Muhlis Cem Ar; Tuğrul Elverdi

doi:10.12659/AOT.947186

11 February 2025 : Original article

Retrospective Study to Compare Outcomes in 159 Patients Undergoing First Autologous Stem Cell Transplantation for Myeloma Treated with Melphalan 140 mg/m² or 200 mg/m²

Umut Yılmaz

^{ABCDEF 1*}, Şükran Erdem Nurcan

^{BC 2}, Deniz Özmen

^{B 1}, Ayşe Salihoğlu^{AB 1}, Ahmet Emre Eşkazan^{ADE 1}, Şeniz Öngören^{AB 1}, Zafer Başlar^{BD 1}, Teoman Soysal

^{ADF 1}, Muhlis Cem Ar^{ADEF 1}, Tuğrul Elverdi^{ACDEF 1}

DOI: 10.12659/AOT.947186

Ann Transplant 2025; 30:e947186

Authors information Article notes Copyright and License information

Introduction Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Figure 3 Kaplan-Meier survival analysis for overall survival (OS) (A) based on melphalan dose at autologous stem cell transplantation (ASCT), and hazard ratios (HR) with confidence intervals from multivariate analysis (B) based on Cox regression analysis are demonstrated. ASCT – autologous stem cell transplantation. IBM SPSS version 20 was used for statistical analysis; plots were re-generated on Microsoft Excell and PowerPoint.

Back to the Article

Retrospective Study to Compare Outcomes in 159 Patients Undergoing First Autologous Stem Cell Transplantation for Myeloma Treated with Melphalan 140 mg/m² or 200 mg/m²

Your Privacy